Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank25
3Y CAGR-44.3%
5Y CAGR-38.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-44.3%/yr
vs -16.4%/yr prior
5Y CAGR
-38.3%/yr
Recent deceleration
Acceleration
-27.9pp
Decelerating
Percentile
P25
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 9.82% |
| 2024 | 0.05% |
| 2023 | 80.69% |
| 2022 | 56.79% |
| 2021 | 26.81% |
| 2020 | 109.78% |
| 2019 | 193.52% |
| 2018 | 116.37% |
| 2017 | 143.10% |
| 2016 | -32.30% |